KIT and melanoma: The identification of the KIT mutation as a poor prognostic factor in high-risk stage II melanomas suggests that testing for this mutation may provide an opportunity for the adjuvant use of KIT inhibitors to treat these otherwise treatment-resistant triple wild-type tumors.